Boyd Street Ventures has announced an investment in biotech company Cadenza Bio. The company focuses on developing small molecules for demyelinating and inflammatory diseases, with a specific focus on multiple sclerosis (MS). Cadenza Bio aims to halt the progression of MS, restore function, and improve the quality of life for patients. The company holds an exclusive license to technology developed through a research collaboration between Dr. John Katzenellenbogen of the University of Illinois Urbana-Champaign and Dr. Seema Tiwari-Woodruff of the University of California, Riverside. Boyd Street Ventures is impressed with the potential of Cadenza Bio and believes that their participation will play a meaningful role in the company’s growth and development.
Boyd Street Ventures backs game-changer, Cadenza Bio’s biotech breakthrough!
Latest from Blog
Arch Venture Partners secures over $3bn for Fund XIII
TLDR: Arch Venture Partners has raised over $3 billion for Fund XIII. Investors in the fund include Alaska Permanent Fund and Rockefeller Brothers Fund. In a recent development, Arch Venture Partners has
Raising Your First Venture Fund: Tips for Success
TLDR: Samir Kaji, a seasoned venture capital professional, shares a six-point plan for raising a venture fund as a first-time fund manager. Key steps include staying focused on a niche, not worrying
Exploring China’s Quantum Computing Breakthrough and VC Trends
TLDR: ONCO stock surged over 80% in pre-market after Altos Venture acquired a stake Chinese low float stocks like DUO rose over 40% in sympathy with large caps Summary: The article discusses
The Blindspot: Venture Capitalists’ Go-To Tool with Fatal Flaw
TLDR: Nader Al-Naji, founder of Bitclout, was arrested for an alleged crypto scam involving VC giant Andreessen Horowitz as a victim. VCs’ pattern matching led them to invest in Al-Naji despite red
Korean startups seek corporate investors in challenging ecosystem climate
TLDR: Korean startups are seeking corporate investors as funding becomes harder to secure. The government in South Korea has relaxed CVC rules to attract more foreign investment. Korean startups are facing a